These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894 [TBL] [Abstract][Full Text] [Related]
5. For patients who inherit homozygous familial hypercholesterolemia, 2 new treatments available. Morrow T Manag Care; 2013 Mar; 22(3):47-8. PubMed ID: 23610808 [No Abstract] [Full Text] [Related]
6. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Rader DJ; Kastelein JJ Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695 [No Abstract] [Full Text] [Related]
7. Two new drugs for homozygous familial hyperchelesterolemia. Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581 [No Abstract] [Full Text] [Related]
8. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice. Marbach JA; Thapa J; Goldenberg E; Duffy D Del Med J; 2015 Aug; 87(8):238-43. PubMed ID: 26402926 [TBL] [Abstract][Full Text] [Related]
9. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Cuchel M; Blom DJ; Averna MR Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075 [TBL] [Abstract][Full Text] [Related]
10. Anacetrapib in familial hypercholesterolaemia: pros and cons. Raal FJ; Blom DJ Lancet; 2015 May; 385(9983):2124-6. PubMed ID: 25743172 [No Abstract] [Full Text] [Related]
11. Severe familial hypercholesterolaemia: current and future management. Farnier M; Bruckert E Arch Cardiovasc Dis; 2012 Dec; 105(12):656-65. PubMed ID: 23199621 [TBL] [Abstract][Full Text] [Related]
12. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. Neef D; Berthold HK; Gouni-Berthold I Expert Rev Clin Pharmacol; 2016; 9(5):655-63. PubMed ID: 26943823 [TBL] [Abstract][Full Text] [Related]
13. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia. Miltiadous G; Saougos V; Cariolou M; Elisaf MS Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279 [TBL] [Abstract][Full Text] [Related]
14. Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia. Baum SJ; Soffer D; Barton Duell P Rev Cardiovasc Med; 2016; 17(1-2):16-27. PubMed ID: 27667377 [TBL] [Abstract][Full Text] [Related]
15. Familial hypercholesterolaemia: clinical features and management. Pottle A Nurs Stand; 2005 Dec 14-2006 Jan 3; 20(14-16):55-65; quiz 66. PubMed ID: 16372559 [TBL] [Abstract][Full Text] [Related]
16. Novel therapies for treating familial hypercholesterolemia. Bandeali SJ; Daye J; Virani SS Curr Atheroscler Rep; 2014 Jan; 16(1):382. PubMed ID: 24293346 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Marais AD; Blom DJ Curr Opin Lipidol; 2013 Aug; 24(4):288-94. PubMed ID: 23839331 [TBL] [Abstract][Full Text] [Related]
18. [The practice guideline 'Diagnosis and treatment of familial hypercholesterolaemia' of the Dutch Health Care Insurance Board]. Walma EP; Visseren FL; Jukema JW; Kastelein JJ; Hoes AW; Stalenhoef AF Ned Tijdschr Geneeskd; 2006 Jan; 150(1):18-23. PubMed ID: 16440619 [TBL] [Abstract][Full Text] [Related]
19. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Elis A; Zhou R; Stein EA Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982 [TBL] [Abstract][Full Text] [Related]